Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

This study has been terminated.
Sponsor:
Collaborators:
The Methodist Hospital System
Texas Children's Hospital
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by:
Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00040469
First received: June 26, 2002
Last updated: April 9, 2007
Last verified: April 2007

June 26, 2002
April 9, 2007
August 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00040469 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease.

We will do this by using three drugs: busulfan, cyclophosphamide, and CAMPATH-1H. CAMPATH-IH is an investigational drug. CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. After the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Sickle Cell Anemia
  • Hemoglobinopathy
  • Thalassemia
  • Drug: Campath -1H
  • Drug: Dilantin
  • Drug: Busulfan
  • Drug: Cyclophosphamide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
15
Not Provided
Not Provided

Inclusion:

  • Patients with homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with an HLA genotypically identical donor.
  • Patients with an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb 0/+ and at least one of the following:

Previous central nervous system vaso-occlusive episode with or without residual neurologic findings; Frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy; Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.

  • Severe anemia which prevents acceptable quality of life and necessitates chronic transfusion therapy.
  • The patient must have an HLA genotype identical donor.
  • Between the ages of birth and 65 years.
  • Women of childbearing potential must have a negative pregnancy test.

Exclusion:

  • Biopsy proven chronic active hepatitis or fibrosis with portal bridging.
  • SCD chronic lung disease >/= stage 3.
  • Severe renal dysfunction defined as creatinine clearance <40 ml/min/1.73 M2
  • Severe cardiac dysfunction defined as shortening fraction <25%.
  • HIV infection.
  • Severe but unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplant (BMT).
  • Inadequate intellectual capacity to understand the nature and risk inherent in the BMT process and give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian).
  • Pregnant, lactating or unwilling to use appropriate birth control.
Both
up to 64 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00040469
H6847, Scallo2
Not Provided
Not Provided
Baylor College of Medicine
  • The Methodist Hospital System
  • Texas Children's Hospital
  • Center for Cell and Gene Therapy, Baylor College of Medicine
Study Chair: Malcolm K. Brenner, MD Baylor College of Medicine
Baylor College of Medicine
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP